Citations

Clear

6274 citation(s) found for "To, Andrew".

Human immunoglobulin G responses to Cimex lectularius L. saliva
Sheele, Johnathan M. , Ferrari, Brian, Schlatzer, Danie, Lundberg, Kathleen C. , Guinto, Katirina, Embers, Monica E. , Young, Andrew B., Ridge, Gale E. , Damiani, Giovanni , Goddard, Jerome , McCormick, Thomas S. , Sheele, Johnathan M

Mayo Clinic

Parasite Immunology | June 9, 2020 | Volume: 42 | Issue: 12 | Pages: No page available

10.1111/pim.12764 | PMID 32516446 Get It

AbstractAimsTo investigate the immunoglobulin (Ig) G response after being fed upon by Cimex lectularius L.Methods and ResultsParticipants were fed upon by three male C lectularius insects weekly for a month. Blood was obtained before the feeding and at the last feeding, which was used for immunoblots against bed bug salivary gland extract, with antihuman Immunoglobulin G (IgG) secondary antibodies. No consistent IgG changes developed in 11 humans serially fed upon by C lectularius. Two participants had new IgG responses to proteins at molecular weights of approximately 12‐13 kDa, and one had an IgG response to a protein at approximately 40 kDa. At the last study visit, more intense IgG bands to proteins at molecular weights of 12‐13 kDa had developed in 55% of participants (6/11) and at molecular weights of ≈30, ≈40 and ≈70 kDa in 45% (5/11) compared with the first study visit. Nitrophorin and apyrase were the most common C lectularius proteins identified with liquid chromatography‐tandem mass spectrometry in both crushed bed bug salivary gland extract and post–bed bug feeding extract.ConclusionsHuman participants did not have consistent IgG responses to crushed C lectularius salivary gland extract.
Interobserver variation in the classification of thymic lesions including biopsies and resection specimens in an international digital microscopy panel
Wolf, Janina , Nederveen, Francien van, Blaauwgeers, Hans, Marx, Alexander, Nicholson, Andrew G. , Roden, Anja C. , Stroebel, Philipp, Timens, Wim , Weissferdt, Annikka , Bakker, Marina, den Bakker, Michael A , Timens, Wim , Nicholson, Andrew , Nederveen, Francien van, Blaauwgeers, Hans, Marx, Alexander, Thüsen, Jan H. von der

Mayo Clinic

Histopathology | June 7, 2020 | Volume: 77 | Issue: 5 | Pages: 734-741

10.1111/his.14167 | PMID 32506527 Get It

AimsThymic tumours are rare in routine pathology practice. Although the World Health Organization (WHO) classification describes a number of well‐defined categories, the classification remains challenging. The aim of this study was to investigate the reproducibility of the WHO classification among a large group of international pathologists with expertise in thymic pathology and by using whole slide imaging to facilitate rapid diagnostic turnover.Methods and resultsThree hundred and five tumours, consisting of 90 biopsies and 215 resection specimens, were reviewed with a panel‐based virtual microscopy approach by a group of 13 pathologists with expertise in thymic tumours over a period of 6 years. The specimens were classified according to the WHO 2015 classification. The data were subjected to statistical analysis, and interobserver concordance (Fleiss kappa) was calculated. All cases were diagnosed within a time frame of 2 weeks. The overall level of agreement was substantial (κ = 0.6762), and differed slightly between resection specimens (κ = 0.7281) and biopsies (κ = 0.5955). When analysis was limited to thymomas only, and they were grouped according to the European Society for Medical Oncology Clinical Practice Guidelines into B2, B3 versus A, AB, B1 and B3 versus A, AB, B1, B2, the level of agreement decreased slightly (κ = 0.5506 and κ = 0.4929, respectively). Difficulties arose in distinguishing thymoma from thymic carcinoma. Within the thymoma subgroup, difficulties in distinction were seen within the B group.ConclusionsAgreement in diagnosing thymic lesions is substantial when they are assessed by pathologists with experience of these rare tumours. Digital pathology decreases the turnaround time and facilitates access to what is essentially a multinational resource. This platform provides a template for dealing with rare tumours for which expertise is sparse.
Study Design and Rationale of EXPLORER-HCM
Ho, Carolyn Y. , Olivotto, Iacopo , Lester, Steven J., Roe, Matthew T. , Wang, Andrew , Waldman, Cynthia Burstein, Sehnert, Amy J. , Olivotto, Iacopo , Wang, Andrew , Ho, Carolyn Y , Jacoby, Daniel Louis , Zhang, David, Heitner, Stephen B.

Mayo Clinic

Circulation: Heart Failure | June 5, 2020 | Volume: 13 | Issue: 6 | Pages: No page available

10.1161/circheartfailure.120.006853 | PMID 32498620 Get It

Background: Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by unexplained left ventricular (LV) hypertrophy associated with dynamic LV outflow tract obstruction. Current medical therapies are nonspecific and have limited efficacy in relieving symptoms. Mavacamten is a first-in-class targeted inhibitor of cardiac myosin, which has been shown to reduce LV outflow tract obstruction, improve exercise capacity, and relieve symptoms of oHCM in the PIONEER-HCM phase 2 study. Methods: EXPLORER-HCM is a multicenter, phase 3, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of mavacamten in treating symptomatic oHCM. Eligible adults with oHCM and New York Heart Association Functional Class II or III are randomized 1:1 to receive once-daily, oral mavacamten, or matching placebo for 30 weeks. The primary composite functional end point is clinical response at week 30 compared to baseline defined as either (1) an increase in peak oxygen consumption ≥1.5 mL/kg/min and reduction of at least one New York Heart Association class; or (2) an improvement of ≥3.0 mL/kg/min in peak oxygen consumption with no worsening of New York Heart Association class. Secondary end points include change in postexercise LV outflow tract gradient, New York Heart Association class, peak oxygen consumption, and patient-reported outcomes assessed by the Kansas City Cardiomyopathy Questionnaire and a novel HCM-specific instrument. Exploratory end points aim to characterize the effect of mavacamten on multiple aspects of oHCM pathophysiology. Conclusions: EXPLORER-HCM is a phase 3 trial in oHCM testing a first-in-class, targeted strategy of myosin inhibition to improve symptom burden and exercise capacity through reducing LV outflow tract obstruction. Results of this trial will provide evidence to support the first disease-specific treatment for HCM. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03470545.
ERCP with overtube-assisted enteroscopy in patients with Roux-en-Y gastric bypass anatomy: a systematic review and meta-analysis
Klair, Jagpal S. , Jayaraj, Mahendran , Chandrasekar, Viveksandeep Thoguluva , Priyan, Harshith, Law, Joanna K. , Murali, Arvind R. , Singh, Dhruv P. , Larsen, Michael , Irani, Shayan , Kozarek, Richard A. , Ross, Andrew S., Krishnamoorthi, Rajesh , Singh, Dhruv

Mayo Clinic

Endoscopy | June 3, 2020 | Volume: 52 | Issue: 10 | Pages: 824-832

10.1055/a-1178-9741 | PMID 32492751 Get It

AbstractBackground Endoscopic retrograde cholangiopancreatography (ERCP) in patients with Roux-en-Y gastric bypass (RYGB) anatomy is challenging. Overtube-assisted enteroscopy (OAE) is usually needed to perform ERCP in these patients. There is significant variation in the reported rates of success and adverse events across published studies. We performed a systematic review and meta-analysis to reliably estimate the pooled rates of success and adverse events.Methods We performed a systematic search of multiple electronic databases through February 2020 to identify studies reporting outcomes of OAE-ERCP in post-RYGB patients. The pooled rates of enteroscopy success, technical success, and adverse events were estimated for OAE-ERCP. The pooled rates of success and adverse events were also estimated for ERCP using double-balloon enteroscopes (DBE) alone.Results 10 studies reporting a total of 398 procedures were included in the meta-analysis. The pooled rates of enteroscopy and technical success of OAE-ERCP were 75.3 % (95 % confidence interval [CI] 64.5 – 83.6) and 64.8 % (95 %CI 53.1 – 74.9) respectively. The pooled rate of adverse events was 8.0 % (95 %CI 5.2 – 12.2). The pooled rates of enteroscopy and technical success of DBE-ERCP (four studies) were 83.5 % (95 %CI 68.3 – 92.2) and 72.5 % (95 %CI 52.3 – 86.4), respectively. The pooled rate of adverse events with DBE-ERCP was 9.0 % (95 %CI 5.4 – 14.5). Substantial heterogeneity was noted.Conclusions OAE-ERCP appears to be effective and safe in post-RYGB patients. Among the currently available techniques, OAE-ERCP is the least invasive approach in this challenging group of patients. Future studies comparing the effectiveness and safety of alternative novel techniques, such as endosonography-directed transgastric ERCP, with OAE-ERCP are needed.
Renal Function Parameters and Serum Sodium Enhance Prediction of Wait‐List Outcomes in Pediatric Liver Transplantation
Thalji, Leanne, Thalji, Nassir M , Ibrahim, Samar H. , Kamath, Patrick S. , Hanson, Andrew C. , Schulte, Phillip J. , Haile, Dawit T. , Kor, Daryl J. , Ibrahim, Samar H , Hanson, Andrew, Heimbach, Julie K.

Mayo Clinic

Hepatology | June 2, 2020 | Volume: 73 | Issue: 3 | Pages: 1117-1131

10.1002/hep.31397 | PMID 32485002 Get It

Background and Aims Reliance on exception points to prioritize children for liver transplantation (LT) stems from concerns that the Pediatric End‐Stage Liver Disease (PELD) score underestimates mortality. Renal dysfunction and serum sodium disturbances are negative prognosticators in adult LT candidates and various pediatric populations, but are not accounted for in PELD. We retrospectively evaluated the effect of these parameters in predicting 90‐day wait‐list death/deterioration among pediatric patients (<12 years) listed for isolated LT in the United States between February 2002 and June 2018. Approach and Results Among 4,765 patients, 2,303 (49.3%) were transplanted, and 231 (4.8%) died or deteriorated beyond transplantability within 90 days of listing. Estimated glomerular filtration rate (eGFR) (hazard ratio [HR] 1.09 per 5‐unit decrease, 95% confidence interval [CI] 1.06‐1.10) and dialysis (HR 7.24, 95% CI 3.57‐14.66) were univariate predictors of 90‐day death/deterioration (P < 0.001). The long‐term benefit of LT persisted in patients with renal dysfunction, with LT as a time‐dependent covariate conferring a 2.4‐fold and 17‐fold improvement in late survival among those with mild and moderate‐to‐severe dysfunction, respectively. Adjusting for PELD, sodium was a significant nonlinear predictor of outcome, with 90‐day death/deterioration risk increased at both extremes of sodium (HR 1.20 per 1‐unit decrease below 137 mmol/L, 95% CI 1.16‐1.23; HR per 1‐unit increase above 137 mmol/L 1.13, 95% CI 1.10‐1.17, P < 0.001). A multivariable model incorporating PELD, eGFR, dialysis, and sodium demonstrated improved performance and superior calibration in predicting wait‐list outcomes relative to the PELD score. Conclusions Listing eGFR, dialysis, and serum sodium are potent, independent predictors of 90‐day death/deterioration in pediatric LT candidates, capturing risk not accounted for by PELD. Incorporation of these variables into organ allocation systems may highlight patient subsets with previously underappreciated risk, augment ability of PELD to prioritize patients for transplantation, and ultimately mitigate reliance on nonstandard exceptions.
Melanoma Treated With Mohs Micrographic Surgery Using a Novel-Modified 15-Minute MART-1 Immunostain: Discussion of Technique and Experience
Cheraghi, Nikoo, Demer, Addison M. , Meister, Andrew, Lee, Peter P.

Mayo Clinic

Dermatologic Surgery | June 1, 2020 | Volume: 47 | Issue: 4 | Pages: 549-551

10.1097/dss.0000000000002435 | PMID 32483096 Get It

Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD
Jitprapaikulsan, Jiraporn , Fryer, James P., Majed, Masoud , Jenkins, Sarah M. , Cabre, Philippe, Hinson, Shannon R., Weinshenker, Brian G. , Mandrekar, Jay , Chen, John J. , Lucchinetti, Claudia F. , Jiao, Yujuan , Segan, Jessica, Schmeling, John E., Mills, John R. , Pittock, Sean J. , Smith, Carin Y. , Weinshenker, Brian G , Pittock, S J , Chen, John J , Flanagan, Eoin P. , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | May 28, 2020 | Volume: 7 | Issue: 4 | Pages: No page available

10.1212/nxi.0000000000000727 | PMID 35413004 Get It

Delayed presentation of acute ischemic strokes during the COVID-19 crisis
Schirmer, Clemens M. , Ringer, Andrew J. , Binning, Mandy J., Fox, W. Christopher , James, Robert F. , Levitt, Michael R. , Veznedaroglu, Erol, Walker, Melanie , Spiotta, Alejandro M , Arthur, Adam Stephen , Levitt, Michael R , Fox, W Christopher , Schirmer, Clemens M , Tawk, Rabih G.

Mayo Clinic

Journal of NeuroInterventional Surgery | May 28, 2020 | Volume: 12 | Issue: 7 | Pages: 639-642

10.1136/neurintsurg-2020-016299 | PMID 32467244 Get It

Background The COVID-19 pandemic has disrupted established care paths worldwide. Patient awareness of the pandemic and executive limitations imposed on public life have changed the perception of when to seek care for acute conditions in some cases. We sought to study whether there is a delay in presentation for acute ischemic stroke patients in the first month of the pandemic in the US. Methods The interval between last-known-well (LKW) time and presentation of 710 consecutive patients presenting with acute ischemic strokes to 12 stroke centers across the US were extracted from a prospectively maintained quality database. We analyzed the timing and severity of the presentation in the baseline period from February to March 2019 and compared results with the timeframe of February and March 2020. Results There were 320 patients in the 2-month baseline period in 2019, there was a marked decrease in patients from February to March of 2020 (227 patients in February, and 163 patients in March). There was no difference in the severity of the presentation between groups and no difference in age between the baseline and the COVID period. The mean interval from LKW to the presentation was significantly longer in the COVID period (603±1035 min) compared with the baseline period (442±435 min, P<0.02). Conclusion We present data supporting an association between public awareness and limitations imposed on public life during the COVID-19 pandemic in the US and a delay in presentation for acute ischemic stroke patients to a stroke center.
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society o
Stanway, Susannah , Brezden‐Masley, Christine , Cohen‐Solal, Alain , Tocchetti, Carlo G. , Moslehi, Javid J. , Groarke, John D. , Bergler‐Klein, Jutta , Khoo, Vincent , Tan, Li Ling , Anker, Markus S. , Haehling, Stephan von , Maack, Christoph , Ky, Bonnie , Neilan, Tomas G. , Rosen, Stuart D. , Iakobishvili, Zaza , Sverdlov, Aaron L. , Hajjar, Ludhmila Abrahão , Macedo, Ariane Vieira Scarlatelli , Manisty, Charlotte , Farmakis, Dimitrios , Boer, Rudolf A. de , Skouri, Hadi , Suter, Thomas, Fradley, Michael G. , Herrmann, Joerg , Cornell, Robert F. , Wechelaker, Ashutosh, Mauro, Michael J. , Milojković, Dragana , Lavallade, Hugues de , Seferović, Petar , Chioncel, Ovidiu , Andrés, María Sol , Wright, David J. , de Boer, Rudolf A , Ky, Bonnie , Sverdlov, Aaron L , Tocchetti, Carlo Gabriele , Lyon, Alexander R. , Dent, Susan , Earl, Helena , Pudil, Radek , Barac, Ana , Thavendiranathan, Paaladinesh , Belenkov, Yu. N. , Ciardiello, Fortunato , Cardinale, Daniela , Witteles, Ronald , Ruschitzka, Frank T. , Coats, Andrew J.S. , Thum, Thomas , Bauersachs, Johann , López‐Fernández, Teresa , Plummer, Chris , Lenihan, Daniel

Mayo Clinic

European Journal of Heart Failure | May 28, 2020 | Volume: 22 | Issue: 11 | Pages: 1945-1960

10.1002/ejhf.1920 | PMID 32463967 Get It

Abstract This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.